Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
APIMEDS PHARMACEUTICALS US Aktie jetzt für 0€ handeln | |||||
23.05. | Apimeds Pharmaceuticals US, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings | ||
20.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
20.05. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
16.05. | D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. in connection with its $13.5 Million Initial Public Offering | 467 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in... ► Artikel lesen | |
12.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.05. | Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering | 94 | GlobeNewswire (Europe) | Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the... ► Artikel lesen | |
09.05. | Apimeds Pharmaceuticals starts trading at $4 per share in line with IPO pricing | 1 | Investing.com | ||
09.05. | Apimeds Pharmaceuticals startet Handel bei 4 US-Dollar je Aktie gemäß Börsengang-Preis | 2 | Investing.com Deutsch | ||
09.05. | Inflammation drug developer Apimeds Pharmaceuticals US prices IPO at $4.00, the low end of the range | 3 | Renaissance Capital | ||
05.05. | IPO Roundup: American Integrity Insurance, Apimeds Pharmaceuticals and more | 1 | Seeking Alpha | ||
02.05. | Apimeds Pharmaceuticals US, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
15.04. | Apimeds Pharmaceuticals US, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
15.04. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.03. | Preview: Apimeds Pharmaceuticals Us, Inc Set To IPO Tomorrow | 20 | Benzinga.com | ||
03.03. | Apimeds Pharmaceuticals US, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
20.02. | Apimeds Pharmaceuticals Us, Inc To Start Trading Tomorrow | 1 | Benzinga.com | ||
06.02. | Apimeds Pharmaceuticals US, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
29.01. | Inflammation biotech Apimeds Pharmaceuticals ups deal size by 74% ahead of $20 million IPO | 3 | Renaissance Capital | ||
29.01. | Apimeds Pharmaceuticals US, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
10.01. | Apimeds Pharmaceuticals US, Inc. - S-1/A, General form for registration of securities | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
BIONTECH | 99,35 | +1,90 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
QIAGEN | 40,300 | -0,06 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
ADMA BIOLOGICS | 20,330 | -0,64 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
89BIO | 10,050 | 0,00 % | 89bio hält Jahreshauptversammlung ab, Direktoren gewählt | ||
ARCUTIS BIOTHERAPEUTICS | 13,260 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung und 19 US-Dollar Kursziel für Arcutis-Aktie | ||
KYMERA THERAPEUTICS | 44,310 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 7,030 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings |